Project Grant R43HL187068
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $326K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98102, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Emory University $100,228 under the Cardiovascular Diseases Research program (CFDA 93.837) on December 1, 2026, to develop a low-cost, point-of-care thrombocytopenia detector for home use. The funded research will optimize a two-part detection system consisting of a blood collection device and an image processing component that quantifies blood clot contraction. The system measures contractile force generated by activated platelets during...
- The National Heart, Lung, and Blood Institute awarded 3D Bioanalytix, Inc. $421,400 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance and validate a structural proteomics platform for early detection of protein misfolding–driven cardiovascular diseases. 3D Bioanalytix will optimize and validate the analytical performance and reproducibility of the Amyfold assay, a mass spectrometry–based blood test designed to detect misfolded transthyretin in...
- The National Heart, Lung, and Blood Institute awarded $598,636 to Spheric Bio Inc. on September 25, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop the EMULAATE platform, a patient-specific left atrial appendage occlusion (LAAO) device for stroke prevention in atrial fibrillation patients. Spheric Bio is developing EMULAATE to assemble fully soft, personalized implants directly inside the patient's body through a minimally invasive approach by delivering,...
- The National Heart, Lung, and Blood Institute awarded Pulsentry, Inc. $309,198 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and prototype an automated detection system for cardiac tamponade using existing fingertip pulse oximeters. Pulsentry will develop machine learning algorithms that analyze pulse waveform perturbations to identify early signs of cardiac tamponade, a medical emergency caused by fluid or clot accumulation around the heart...
- The National Heart, Lung, and Blood Institute awarded Actiox LLC $699,468 on September 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) for development of a wearable microneedle-based biosensor for continuous cardiac troponin I monitoring. The assistance type is a Project Grant. Actiox will develop and optimize an electrochemical aptamer-based sensor integrated with microneedle arrays capable of real-time, ultra-sensitive monitoring of cardiac troponin I in interstitial...
- The National Heart, Lung, and Blood Institute awarded $351,388 to Barron Associates, Inc. on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a noninvasive hemodynamic monitoring tool for heart failure patients. The project addresses the clinical gap in home and hospital monitoring of acute decompensated heart failure by creating a low-cost alternative to invasive right heart catheterization and costly implantable devices. The proposed solution...
- The National Heart, Lung, and Blood Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded $1,733,846 to The Children's Hospital Corporation, doing business as Boston Children's Hospital, on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate emperipolesis as a driver of platelet heterogeneity and function. The award funds basic science research examining how neutrophils interact with megakaryocytes...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $297,587 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to General Fluidics Corporation to validate the performance of the AXESS system, a novel point-of-need clinical chemistry and hematology platform. The goal is to demonstrate equivalence between the AXESS system's results and those obtained from standard venous blood testing for a basic metabolic panel and complete blood count, using matched capillary and...
- The National Heart, Lung, and Blood Institute awarded Bridgesource Medical, Corp. $320,727 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a right heart catheter device that uses pressure-volume loop analysis to identify which patients with tricuspid regurgitation will benefit from percutaneous valve repair procedures. The device addresses a critical clinical gap in patient selection for tricuspid valve interventions. Approximately 1.5 million...
- The National Heart, Lung, and Blood Institute awarded the Scripps Research Institute $1,101,338 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to engineer noncovalent antibody-enzyme thrombolytic complexes that function orthogonally to the natural hemostatic system. The project, R01HL184492, addresses limitations of current plasminogen activator therapies—including narrow therapeutic window, contraindications, and risks of neurotoxicity, bleeding, and...